IMR Press / EJGO / Volume 25 / Issue 1 / pii/2004106

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research

Treatment policy of neuroendocrine small cell cancer of the cervix

Show Less
1 University Hospital Antwerp. Department of Gynaecologic Oncology, Edegem (Belgium)
2 University Hospital Antwetp, Department of Pathology, Edegem (Belgium)
Eur. J. Gynaecol. Oncol. 2004, 25(1), 40–44;
Published: 10 February 2004
Abstract

Small cell cancers of the cervix are very rare and aggressive tumours. It is difficult to manage these tumours. They are often diag­nosed in an advanced stage and their prognosis is generally poor. There are no clinical trials, due to their rarity, that would suggest optimal treatment. The present report describes a patient with a neuroendocrine small cell cancer of the cervix Stage IB2 with a positive lymph node. The treatment consisted of radical hysterectomy and node dissection, adjuvant chemotherapy, chemoradiation and brachytherapy. Currently, after 52 months, the patient is well and free of disease. Since 1996, there has been a classification for neuroendocrine tumours (NETs) of the cervix in four categories (large cell, small cell, typical carcinoid and atypical carcinoid). The aggressive behaviour of neuroendocrine small cell cancer is demonstrated by the high percentage of early lymphatic node and vessel invasion (68 and 90%). Almost half of the patients with Stage I and II will recur with an estimated 5-year survival from 14% to a maximum of 55%. Multimodal therapy for these tumours appears to give good response but often implies severe side-effects.

Keywords
Small cell
Cancer
Cervix
Neuroendocrine
Tumour
Multimodal treatment
Radical surgery
Chemoradiation
Share
Back to top